Long‐term safety and efficacy of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis

Abstract

Objective. Previous studies showed that etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA) provided rapid clinical improvement that was sustained for up to 2 years. The goal of our study was to provide data on safety and efficacy after 4 years of etanercept treatment in patients with JRA. Conclusion. Etanercept offers an acceptable safety profile in children with polyarticular-course JRA and provides significant improvement in disease manifestations that are sustained for >4 years.

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study

“…There were no reports of opportunistic infections. These results are generally consistent with safety data for other biologic therapy (etanercept) in JRA [31][32][33].…”

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

“…The introduction of biologics like etanercept had a major impact on the outcome of patients with polyarticular JIA. The safety and the efficiency of etanercept had been proved in open and controlled studies as well as in long term studies (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13).…”

Overlapping juvenile idiopathic arthritis and systemic lupus erythematosus: a case report

“…Anti-TNF therapies are promising new strategies in the treatment not only in adult RA but in JIA, as well (23,(33)(34)(35)(36). Despite good clinical efficacy and tolerance, the possible occurrence of drug-induced autoimmune disorders remains a matter of concern.…”

“…ATIL can occur with any of the available TNF-inhibitors, but the frequency and clinical characteristics of ATIL vary between different drugs (34).…”